32 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
16 Apr 24
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
2:39pm
in the treatment of this chronic disease.”
Recent Preclinical Data
Data from a recent proof of concept study indicates that INM-089 may be more effective
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Feb 24
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
7:34pm
believes that INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments. The Company is currently seeking
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
16 Jan 24
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
2:12pm
of chronic itch and other related ailments and the Company is currently seeking partnerships for continued development. Due to several factors, including
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
14 Nov 23
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
4:36pm
, potentially encompassing broader indications related to chronic itch with larger target populations and potential commercial opportunities. The Company
8-K
EX-99.1
af2vt3sstkrzv3 uj5
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
88tcwxq 2xm1v
22 Jun 23
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
4:28pm
424B3
dh6bi zv5
6 Jul 22
Prospectus supplement
2:43pm
424B5
21reoue
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
slkdrl
25 Apr 22
Prospectus supplement
5:02pm
424B3
bchmuj1440 16yx9qk
7 Apr 22
Prospectus supplement
4:46pm
S-3
2gs6428z7cpied
4 Feb 22
Shelf registration
4:36pm
10-K
5u75p59ldumnkt0vnrg
24 Sep 21
Annual report
7:31am
424B3
i31 r8xsu7vsr3s
22 Jul 21
Prospectus supplement
10:27am